Bausch Health Americas, Inc.
Clinical trials sponsored by Bausch Health Americas, Inc., explained in plain language.
A subsidiary of Bausch Health, focused on pharmaceuticals and medical devices in the Americas.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for kids with colitis: budesonide pill trial aims for remission Results expected Dec 2026 (estimated)
- New radiofrequency treatment aims to tighten sagging skin without surgery Results expected Feb 2027 (estimated)
- New hope for Kids' diarrhea: drug plus fluids tested Results expected Apr 2027 (estimated)
-
New foam treatment could help kids with colitis avoid stronger drugs
Disease control Not yet recruitingThis study tests a steroid foam (budesonide) given rectally to children aged 5 to 17 with mild to moderate ulcerative colitis in the lower colon. The goal is to see if it can safely induce remission after 6 weeks of treatment. About 100 children will receive either a low dose, hi…
Phase 4 • Sponsor: Bausch Health Americas, Inc. • Aim: Disease control
Last updated Jun 26, 2026 18:42 UTC
-
New hope for young minds: depression drug trial for children
Symptom relief Not yet recruitingThis study tests whether bupropion hydrobromide (Aplenzin) can safely ease depression symptoms in children and adolescents aged 7 to 17. About 246 participants will receive either the drug or a placebo. The main goal is to see if depression scores improve by the end of treatment.
Phase 4 • Sponsor: Bausch Health Americas, Inc. • Aim: Symptom relief
Last updated Jun 26, 2026 18:44 UTC